ibuviva
pinewood laboratories limited - ibuprofenas - geriamoji suspensija - 200 mg/5 ml; 100 mg/5 ml - ibuprofen
paracetamol/ascorbic acid/pheniramine norpharm
norpharm regulatory services ltd. - paracetamolis/askorbo rūgštis/feniramino maleatas - granulės geriamajam tirpalui - 500 mg/200 mg/25 mg - paracetamol, combinations excl. psycholeptics
paracetamol/ibuprofen vale
vale pharmaceuticals limited - paracetamolis/ibuprofenas - infuzinis tirpalas - 10 mg/3 mg/ml - paracetamol, combinations excl. psycholeptics
bortezomib stada
stada arzneimittel ag - bortezomibas - injekcinis tirpalas - 2,5 mg/ml - bortezomib
ranolazine stada
stada arzneimittel ag - ranolazinas - pailginto atpalaidavimo tabletės - 375 mg - ranolazine
ranolazine stada
stada arzneimittel ag - ranolazinas - pailginto atpalaidavimo tabletės - 500 mg - ranolazine
ranolazine stada
stada arzneimittel ag - ranolazinas - pailginto atpalaidavimo tabletės - 750 mg - ranolazine
kinpeygo
stada arzneimittel ag - budesonide, micronised - glomerulonephritis, iga - antidiarrheals, žarnyno priešuždegiminiai / antiinfective agentų - kinpeygo is indicated for the treatment of primary immunoglobulin a (iga) nephropathy (igan) in adults at risk of rapid disease progression with a urine protein-to-creatinine ratio (upcr) ≥1. 5 g/gram.
ximluci
stada arzneimittel ag - ranibizumabas - wet macular degeneration; macular edema; diabetic retinopathy; diabetes complications - oftalmologai - ximluci is indicated in adults for:the treatment of neovascular (wet) age-related macular degeneration (amd)the treatment of visual impairment due to diabetic macular oedema (dme)the treatment of proliferative diabetic retinopathy (pdr)the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)the treatment of visual impairment due to choroidal neovascularisation (cnv).